Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BeiGene
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women between the age of 18-75 years.
Participants with B-cell lymphoma (defined by World Health Organization classification) refractory or relapsed following at least one line of therapy.
Judged by the investigator as requiring treatment.
Eastern Cooperative Oncology Group performance status of 0-1.
Life expectancy of at least 4 months.
Adequate hematological function.
Adequate renal function.
Adequate liver function.
Adequate coagulation function.
Female participants of childbearing potential and non-sterile males must have practiced at least one of the following methods of birth control with partner(s) throughout the study and for 90 days after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, intrauterine device or hormonal contraceptive initiated at least 3 months prior to first dose of study drug.
Male participants must not have donated sperm from start of study drug administration, until 90 days after discontinuation of treatment.
You may not be if
With central nervous system involvement of the disease.
The pathological type of the disease had disease transformation.
Had underdone allogeneic hematopoietic stem cell transplantation.
Had received corticosteroid anti-neoplastic treatment within 7 days before the first dose, has received radiotherapy and chemotherapy within 4 weeks before the first dose or has received treatment with monoclonal antibody within 4 weeks before the first dose.
Had received BTK inhibitor treatment prior to enrollment.
Had received chemotherapy and has not yet recovered from toxicity
Had received Chinese herbal medicine as anti-neoplastic therapy within 4 weeks before starting study treatment.
History of other malignancies within 2 years before study.
With uncontrolled systemic infection.
Major surgery in the past 4 weeks.
With known HIV, or active hepatitis B or hepatitis C virus infection.
With cardiovascular disease of New York Heart Association Classification ≥ 3.
Significant electrocardiogram abnormalities.
Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participation in the study.
Inability to comply with study procedures.
Was currently taking anticoagulant drugs.
Was currently taking potent cytochrome P450 3A inhibitor or inducer.
Had stroke or cerebral hemorrhage within 6 months before enrollment.
Clareo Health | A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
